{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:44:34Z","timestamp":1792773874118,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.aohep.2026.102476","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:22:33Z","timestamp":1792772553000},"page":"102476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic advances in chronic hepatitis B and Delta: where are we now and where are we headed?"],"prefix":"10.1016","author":[{"given":"Anna","family":"Pocurull","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0326-7088","authenticated-orcid":false,"given":"Sara","family":"Battistella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela","family":"Lens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2026.102476_bib0001","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","author":"Razavi-Shearer","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0002","unstructured":"World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Https:\/\/WwwWhoInt\/Publications\/i\/Item\/9789240090903 2024."},{"key":"10.1016\/j.aohep.2026.102476_bib0003","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001092","article-title":"Association of HDV infection and HCC, hepatic decompensation, and all-cause and liver-related death in a national cohort","volume":"81","author":"John","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102476_bib0004","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1056\/NEJMra2212151","article-title":"Hepatitis D Virus Infection","volume":"389","author":"Asselah","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.aohep.2026.102476_bib0005","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2026.101741","article-title":"Elebsiran and pegylated-IFN\u03b1: Progress toward a functional cure for chronic hepatitis B","volume":"8","author":"Battistella","year":"2026","journal-title":"JHEP Reports"},{"key":"10.1016\/j.aohep.2026.102476_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/v9060156","article-title":"The role of cccDNA in HBV maintenance","volume":"9","author":"Allweiss","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.aohep.2026.102476_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2024.06.037","article-title":"Hepatitis B virus DNA integration: Implications for diagnostics, therapy, and outcome","volume":"81","author":"Zoulim","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0009","doi-asserted-by":"crossref","DOI":"10.1038\/s41575-019-0196-9","article-title":"Restoring, releasing or replacing adaptive immunity in chronic hepatitis B","volume":"16","author":"Maini","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0010","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2468-1253(18)30007-4","article-title":"Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand","volume":"3","author":"Maini","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0011","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/apt.16659","article-title":"Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B","volume":"55","author":"Vittal","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2026.102476_bib0012","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000431","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference","volume":"78","author":"Ghany","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102476_bib0013","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102476_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","author":"Cornberg","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.01.007","article-title":"Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels","volume":"76","author":"Sonneveld","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.12.018","article-title":"A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B","volume":"78","author":"van B\u00f6mmel","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0017","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2026.102476_bib0018","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70371","article-title":"Determinants of HBsAg Loss After Nucleos(t)ide Discontinuation in a Prospective Cohort of HBeAg-Negative Caucasian Patients","volume":"45","author":"Pocurull","year":"2025","journal-title":"Liver International"},{"key":"10.1016\/j.aohep.2026.102476_bib0019","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-023-02852-x","article-title":"Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation","volume":"23","author":"Xie","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.aohep.2026.102476_bib0020","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.13729","article-title":"Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy","volume":"29","author":"Papatheodoridi","year":"2022","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.aohep.2026.102476_bib0021","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.aohep.2026.102476_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2024.05.001","article-title":"Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial","volume":"81","author":"Wedemeyer","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2026.03.046","article-title":"144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial","author":"Wedemeyer","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0024","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.70056","article-title":"Bulevirtide Monotherapy or in Combination for Chronic Hepatitis Delta: 2025 Update","volume":"32","author":"Lampertico","year":"2025","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.aohep.2026.102476_bib0025","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2314134","article-title":"Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D","volume":"391","author":"Asselah","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.aohep.2026.102476_bib0026","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000847","article-title":"Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis - A real-world case series","volume":"80","author":"Dietz-Fricke","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102476_bib0027","doi-asserted-by":"crossref","DOI":"10.3350\/cmh.2022.0012","article-title":"RNA interference as a novel treatment strategy for chronic hepatitis B infection","volume":"28","author":"Hui","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0028","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.aohep.2026.102476_bib0029","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2405485","article-title":"Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B","volume":"391","author":"Hou","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.aohep.2026.102476_bib0030","doi-asserted-by":"crossref","DOI":"10.1261\/rna.079699.123","article-title":"Localization of unlabeled bepirovirsen antisense oligonucleotide in murine tissues using in situ hybridization and CARS imaging","volume":"29","author":"Spencer-Dene","year":"2023","journal-title":"RNA"},{"key":"10.1016\/j.aohep.2026.102476_bib0031","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection","volume":"387","author":"Yuen","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.aohep.2026.102476_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2024.08.010","article-title":"Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B","volume":"82","author":"Buti","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0033","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2468-1253(23)00148-6","volume":"8","author":"Yuen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(24)00237-1","article-title":"VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study","volume":"9","author":"Yuen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0035","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/S0168-8278(22)00537-2","article-title":"Longer treatment duration of monthly VIR-2218 results in deeper and more sustained reductions in hepatitis B surface antigen in participants with chronic hepatitis B infection","volume":"77","author":"Lim","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0036","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2405485","article-title":"Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B","volume":"391","author":"Hou","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.aohep.2026.102476_bib0037","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-04049-z","article-title":"Elebsiran and PEG-IFN\u03b1 for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial","volume":"32","author":"Wong","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.aohep.2026.102476_bib0038","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2025-336592","article-title":"Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT study","volume":"75","author":"Kennedy","year":"2026","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2026.102476_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2024.03.046","article-title":"JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2","volume":"81","author":"Agarwal","year":"2024","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.aohep.2026.102476_bib0040","first-page":"S47","volume":"78","author":"MacQuillan","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102476_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(25)00293-6","article-title":"ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial","volume":"11","author":"Yuen","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106446","article-title":"Efficacy and safety of GLS4 with entecavir vs entecavir alone in chronic hepatitis B patients: A multicenter clinical trial","volume":"90","author":"Zhang","year":"2025","journal-title":"Journal of Infection"},{"key":"10.1016\/j.aohep.2026.102476_bib0044","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Na\u00efve to Nucleos(t)ide Therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2026.102476_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.09.027","article-title":"Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression","volume":"78","author":"Gane","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2024.06.027","article-title":"Phase Ib\/IIa randomized study of heterologous ChAdOx1-HBV\/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB","volume":"81","author":"Tak","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2021.100361","article-title":"Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib\/IIa study","volume":"3","author":"Ma","year":"2021","journal-title":"JHEP Reports"},{"key":"10.1016\/j.aohep.2026.102476_bib0048","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-04049-z","article-title":"Elebsiran and PEG-IFN\u03b1 for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial","volume":"32","author":"Wong","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.aohep.2026.102476_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102641","article-title":"MVA-HBVac\u2014A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccination","volume":"36","author":"Kosinska","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.aohep.2026.102476_bib0050","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral Intrahepatic T-Cell Responses Can Be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.aohep.2026.102476_bib0051","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70338","article-title":"HBV suppression by nucleos(t)ide analogues reduces PD-1 expression on liver-resident T cells","volume":"45","author":"Garc\u00eda-L\u00f3pez","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2026.102476_bib0052","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jhep.2024.07.018","article-title":"Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy","volume":"82","author":"Mon","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0053","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001006","article-title":"A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally suppressed patients with chronic hepatitis B who are HBeAg-negative","volume":"81","author":"Qian","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102476_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(23)00488-9","article-title":"Safety and antiviral activity of short-duration combinations of the investigational small interfering ribonucleic acid VIR-2218 with the neutralizing, vaccinal monoclonal antibody VIR-3434: post-treatment follow-up from the Phase 2 MARCH trial","volume":"78","author":"Gane","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2024.06.027","article-title":"Phase Ib\/IIa randomized study of heterologous ChAdOx1-HBV\/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB","volume":"81","author":"Tak","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.aohep.2026.102476_bib0057","first-page":"S230","article-title":"Combination therapy with TLR7 agonist TQ-A3334 and anti-PD-L1 TQ-B2450 enhance HBsAg decline in virally suppressed patients with chronic hepatitis B: OCEANcure05 study","volume":"80","author":"Wu","year":"2024","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.aohep.2026.102476_bib0058","first-page":"S258","article-title":"A phase 1b, open-label study to evaluate the safety and efficacy of novel hepatitis B virus combination therapies in patients living with chronic hepatitis B","volume":"80","author":"Gane","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102476_bib0059","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2405485","article-title":"Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B","volume":"391","author":"Hou","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.aohep.2026.102476_bib0060","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.dld.2025.01.049","article-title":"Evidence of durable response to bepirovirsen in B-Clear On-NA responders: B-Sure second report","volume":"57","author":"Lim","year":"2025","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.aohep.2026.102476_bib0061","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2024-333026","article-title":"Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989","volume":"74","author":"Mak","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2026.102476_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(24)00472-0","article-title":"OS-031 Imdusiran (AB-729) administered every 8 weeks for 24 weeks followed by the immunotherapeutic VTP-300 maintains lower HBV surface antigen levels in NA-suppressed CHB subjects than 24 weeks of imdusiran alone","volume":"80","author":"Agarwal","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0063","unstructured":"Wong GLH, Yuen MF, Kennedy P, Brown A, Chen CY, Lo GH, et al. Preliminary antiviral efficacy and safety of repeat dosing of imdusiran (AB-729) followed by VTP-300 with or without nivolumab in virally suppressed, non-cirrhotic subjects with chronic hepatitis B (CHB). The Liver Meeting (AASLD); November 15\u201319, 2024; San Diego, CA, USA. Abstract 5025. https:\/\/www.natap.org\/2024\/AASLD\/AASLD_48.htm"},{"key":"10.1016\/j.aohep.2026.102476_bib0064","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S0168-8278(24)00572-5","article-title":"LBP-005 Efficacy, safety, tolerability, and immunogenicity of JNJ-0535 following a reduction of viral antigen levels through administration of siRNA JNJ-3989 in patients with chronic HBeAg negative hepatitis B-interim data of the OSPREY study","volume":"80","author":"Bourgeois","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0065","unstructured":"Ji Y, Le Bert N, Ma H, et al. BRII-179 induced distinct anti-HBs antibody responses in chronic hepatitis B subjects with diverse underlying impairment of humoral immunity. The Liver Meeting (AASLD); November 10\u201314, 2023; Boston, MA, USA. Poster 5022-C."},{"issue":"Suppl 1","key":"10.1016\/j.aohep.2026.102476_bib0066","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0168-8278(24)00471-9","article-title":"Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)","volume":"80","author":"Hou","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0067","unstructured":"Wong GLH, Lim SG, Agarwal K, Avihingsanon A, Lim YS, Sowah L, et al. Results from a phase 2a, open-label study to evaluate the safety and efficacy of novel combination therapies containing VIR-2218, selgantolimod, and nivolumab for the treatment of chronic hepatitis B. The Liver Meeting (AASLD); November 15\u201319, 2024; San Diego, CA, USA. Poster 1380. https:\/\/www.askgileadmedical.com\/docs\/conference\/HBV_AASLD%202024_HBV%20Cure%20Phase2a_1380_Wong_SUBMITTED%40pdf"},{"key":"10.1016\/j.aohep.2026.102476_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(24)00474-4","article-title":"OS-033 A phase 2 open-label study to evaluate safety, tolerability, efficacy, and pharmacodynamics of JNJ-73763989, nucleos (t)ide analogs, and a low-dose PD-1 inhibitor in patients with chronic hepatitis B-Interim results of the OCTOPUS-1 study","volume":"80","author":"Asselah","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0069","unstructured":"Gane E, Agarwal K, Heo J, Jucov A, Lim YS, Streinu-Cercel A, et al. Tobevibart (VIR-3434) and elebsiran (VIR-2218) with or without pegylated interferon alfa-2a for the treatment of chronic HBV infection: end of treatment results after 48 weeks of therapy (MARCH study). The Liver Meeting (AASLD); November 15\u201319, 2024; San Diego, CA, USA. https:\/\/www.natap.org\/2024\/AASLD\/AASLD_52.htm"},{"key":"10.1016\/j.aohep.2026.102476_bib0070","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-019-03021-8","article-title":"Orthologous CRISPR\/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus","volume":"76","author":"Kostyushev","year":"2019","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.aohep.2026.102476_bib0071","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.3748\/wjg.v21.i32.9554","article-title":"Dual gRNAs guided CRISPR\/Cas9 system inhibits hepatitis B virus replication","volume":"21","author":"Wang","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.aohep.2026.102476_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2026.106355","article-title":"Overview of gene editing strategies against HBV","volume":"247","author":"Janetzki","year":"2026","journal-title":"Antiviral Res"},{"key":"10.1016\/j.aohep.2026.102476_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102112","article-title":"Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression in vitro and in vivo","volume":"35","author":"Smekalova","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.aohep.2026.102476_bib0074","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0168-8278(24)00534-8","article-title":"OS-093 Efficient and heritable elimination of HBV viral antigens in vivo by epigenome editing","volume":"80","author":"Peng","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2024.07.007","article-title":"Precision epigenetic editing: Technological advances, enduring challenges, and therapeutic applications","volume":"31","author":"Roth","year":"2024","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.aohep.2026.102476_bib0076","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.116.022188","article-title":"Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome","volume":"134","author":"Gordon","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.aohep.2026.102476_bib0077","doi-asserted-by":"crossref","DOI":"10.1002\/hep.29658","article-title":"Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study","volume":"67","author":"Yurdaydin","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102476_bib0078","doi-asserted-by":"crossref","DOI":"10.1080\/14787210.2023.2159379","article-title":"Epidemiology, presentation, and therapeutic approaches for hepatitis D infections","volume":"21","author":"Blaney","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.aohep.2026.102476_bib0079","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S0168-8278(23)00451-8","article-title":"Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta","volume":"78","author":"Etzion","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2025.10.029","article-title":"Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program","volume":"84","author":"Stern","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102476_bib0081","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2508827","article-title":"A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D","volume":"394","author":"Asselah","year":"2026","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.aohep.2026.102476_bib0082","doi-asserted-by":"crossref","first-page":"S811","DOI":"10.1016\/S0168-8278(24)02239-6","article-title":"WED-374 Safety, tolerability, and pharmacokinetics of BJT-778, a monoclonal antibody for treatment of chronic hepatitis B and chronic hepatitis D, following single ascending doses in healthy volunteers","volume":"80","author":"Gane","year":"2024","journal-title":"J Hepatol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126002966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126002966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:22:44Z","timestamp":1792772564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268126002966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":82,"alternative-id":["S1665268126002966"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102476","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic advances in chronic hepatitis B and Delta: where are we now and where are we headed?","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102476"}}